hydroxytamoxifen that is then converted to the sulfate ester (8) (9) (10) . When tamoxifen is given to female λ/lacI transgenic 4 To whom correspondence should be addressed rats hepatic DNA damage leads to an increase in the frequency Email: iw6@le.ac.uk of gene mutations at lacI (11) . In treated women there is It is now generally accepted that activation of tamoxifen evidence for an increased incidence of uterine endometrial occurs as a result of metabolism to α-hydroxytamoxifen.
(2,12) but not liver tumours (13). The presence of DNA In this study, α-hydroxytamoxifen was given to female damage in the target cells of tamoxifen treated women is Wistar/Han rats (0.103 or 0.0103 mmol/kg, intraperitonecontroversial (14), and even if low levels of damage occurs ally, daily for 5 days). This resulted in liver DNA damage, (7) , it is questionable if this is causally related to the increase determined by 32 P-post-labelling, of 3333 ⍨ 795 or 343 ⍨ in endometrial tumours (15, 16) . The role of α-hydroxytamox-68 adducts/10 8 nucleotides, respectively (mean ⍨ SD, ifen as a carcinogen or mutagen in rats or humans in vivo has n ⍧ 4). Following HPLC separation, the retention times not been established. In this study, the relationship between of the major α-hydroxytamoxifen DNA adducts were sim-DNA damage resulting from the administration to rats of ilar to those seen following the administration of tamoxifen.
α-hydroxytamoxifen and the subsequent development of liver However, after rats were treated with α-hydroxytamoxifen lesions is investigated. (0.103 mmol/kg) for 5 days and the animals kept for up to 13 months, no liver tumours developed (0/7 rats), even Materials and methods with phenobarbital promotion (0/5 rats). GST-P foci were detected in the liver, but only after 13 months was their Animals and treatments number or area significantly increased over the correspondtrans α-Hydroxytamoxifen was prepared according to published procedures (17, 18) . Female 6 week-old Wistar/Han rats were obtained from Harlan Olac ing controls. When α-hydroxytamoxifen was given to female (Bicester, UK). 120 animals were housed in negative pressure isolators with λ/lacI transgenic rats (0.103 mmol/kg orally for 10 days) a 12 h light/dark cycle at 19-22°C. Animals were dosed with and the animals killed 46 days later, there was an approxi-α-hydroxytamoxifen dissolved in tricaprylin, 40 animals at 0.103 mmol/kg mate 1.8-fold increase in mutation frequency but no and 40 animals at 0.0103 mmol/kg, intraperitoneally (40 and 4 mg/ml, significant increase in G:C to T:A transversions as described respectively) daily for 5 days, while controls received tricaprylin only. At the end of the dosing period animals were divided into two groups. One group after tamoxifen treatment. It is concluded that DNA damage of 54 rats was subsequently given water supplemented with 0.1% (w/v) alone, resulting from the short-term administration of phenobarbital and 54 rats received no phenobarbital water supplement. At The anti-oestrogenic drug tamoxifen is widely used as adjuvant mmol/kg. In this assay, animals were dosed by gavage for 10 days. A control therapy in the treatment of breast cancer in women (1). This group of 10 animals received tricaprylin (1 ml/kg/day) for 10 days. For the lacI mutation assay, all the animals were killed 46 days after the last dose. drug may also be effective in the chemoprevention of breast
The diet was withdrawn 24 h prior to killing.
cancer (2). The optimum duration of treatment has not been incidence of hepatocellular carcinomas (4), while in Sprague-
Mutant frequency at lacI gene in the liver
The lacI mutation assay and the DNA sequence analysis of mutant lacI genes was performed as described previously (11) . Sequencing of the doubleAbbreviations: BrdU, 5-bromodeoxyuridine; GST-P, placental form of glutathione S-transferase; PB, phenobarbital; PCNA, proliferating cell nucstranded DNA was carried out in both directions for 25 of the control-derived mutants and 23 of the α-hydroxytamoxifen-derived mutants. lear antigen.
Isolation of hepatocytes
treatment. There was no biliary proliferation in either of the Hepatocytes were isolated from rats treated with α-hydroxytamoxifen, corresponding control groups. There was no difference in 0.103 mmol/kg intraperitoneally for 5 days or tricaprylin vehicle and killed overall cell proliferation in the liver BrdU labelling index on day 6. A two stage collagenase perfusion was used (19) . This yields cell between the α-hydroxytamoxifen dosed rats and their controls preparations consisting of Ͼ90% hepatocytes. Only preparations of Ͼ85%
(not shown).
viability were used, as judged by Trypan blue exclusion and counting with a haemocytometer.
Liver DNA damage caused by α-hydroxytamoxifen and tamox- 32 
P-Post-labelling analysis ifen in Wistar/Han rats
Adducts were determined in DNA isolated from livers or hepatocytes using After dosing rats with α-hydroxytamoxifen at 0.103 or 0.0103 the 32 P-post-labelling assay as described previously (20). mmol/kg for 5 days, total liver DNA damage, as determined
Immunodetection of liver GST-P and cell proliferation by PCNA expression by 32 P-post-labelling 24 h after the last dose and at 3 months For the detection of GST-P foci, paraffin sections (5 µm) from acetone-fixed after cessation of dosing, is shown in Figure 1 . Following the livers were rehydrated and GST-P proteins were located immunohistochemically using an anti-GST-P polyclonal antibody (1:100 dilution) followed by separation of these adducts by HPLC, qualitatively, the pattern an anti-rabbit alkaline phosphatase conjugated second antibody (1:50 dilution; was very similar to that seen in DNA extracted from the livers Sigma). Bound antibody was detected using naphthol AS/BI phosphate and of tamoxifen dosed animals with two major and up to 10 Fast Red TR as described previously (6). GST-P foci were defined as groups minor components (Figure 2 ). The pattern of adducts did not of five or more cells. Foci were counted on at least 1 cm -2 of liver sections change between day 6 and day 90 time points (not shown).
from animals at each time point. Areas of foci were calculated using an Analytical Measuring Systems VIDS V Imaging System (Synopics, At 6 and 13 month time points, adduct levels in the livers of Cambridge, UK) and were expressed as number/cm -2 . For cell proliferation dosed rats did not differ from those of controls. Rats given determination using PCNA, 5 µM paraffin sections from Carnoy's-fixed liver tamoxifen (0.103 mmol/kg, intraperitoneally for 5 days)
were rehydrated and PCNA antigen detected using a monoclonal mouse antishowed less total DNA damage by 32 those seen in whole liver. At day 6, no damage could be the groups. Results were considered to be significant at P Ͻ 0.05. detected in uterine DNA from treated rats above control values.
Results

Mutant frequency at the lacI gene and DNA adducts in the livers of Big Blue rats Life time effects and mortality
Forty-six days following oral dosing with α-hydroxytamoxifen Dosing for 5 days with α-hydroxytamoxifen at 0.103 or 0.0103 (0.103 mmol/kg, for 10 days), the average mutation frequency, mmol/kg did not result in subsequent reduced body weight in the treated group (9.48ϫ10 -5 ) was approximately 1.8-fold gain, known to be associated with long-term anti-oestrogen higher than in the corresponding controls (5.04ϫ10 -5 , treatment of female rats (21) . Additionally, there was not the P Ͻ 0.05) ( Table II) . The type and location of lacI mutations alopecia seen in rats during long-term dosing with tamoxifen from control and α-hydroxytamoxifen treated animals are (22) . There were unscheduled deaths in all treatment groups.
shown in Figure 3 . The frequency of point mutations was 93 Between 9 and 12 months after dosing, 10 animals developed Ϯ 4% in the treated group and 81 Ϯ 4% in the control group. overgrown incisors associated with jaw misalignment. This GC to AT transitions were the most common point mutations effect was not treatment related. On an animal welfare basis, in both control and treated groups. GC to TA transversions in the study was terminated at 13 months.
the tamoxifen treated group (17 Ϯ 6%) were not significantly Liver pathology and GST-P foci with α-hydroxytamoxifen higher than in the control group (9 Ϯ 5%). Immediately after treatment dosing with α-hydroxytamoxifen (0.103 mmol/kg), hepatic At the 3, 6 and 13 month kill periods in the livers of α-DNA damage in these animals, determined by 32 P-post-labelhydroxytamoxifen treated rats, there was a low incidence of ling was 411 Ϯ 192 adducts/10 8 nucleotides (mean Ϯ SD, GST-P positive foci. These foci increased in number and area n ϭ 4). Rats killed at the time of the mutation assay showed with time after treatment but became significant, relative to DNA damage of 66 Ϯ 14 and 3.5 Ϯ 1.7 adducts/10 8 nucleotides the corresponding controls, only in animals killed at 13 in dosed and control rats, respectively. months (Table I ). In the α-hydroxytamoxifen treated groups, phenobarbital treatment did not result in any significant differDiscussion ence in the number or area of foci relative to animals not exposed to phenobarbital. At the lower dose of α-hydroxytaThis study shows that treatment of rats with α-hydroxytamoxifen for 5 days was sufficient to cause cumulative hepatic moxifen (0.0103 mmol/kg for 5 days), occasional GST-P foci were seen at 6 and 13 months after dosing, but the number and DNA damage, as measured by 32 P-post-labelling, in the order of 3300 adducts/10 8 nucleotides. When Wistar rats were given areas were not significantly different from the corresponding control values. Rats given 0.103 mmol/kg α-hydroxytamoxifen dietary tamoxifen for 3 months and then returned to a normal diet, hepatic DNA damage of about 700 adducts/10 8 nucleoand killed at 3, 6 and 13 months showed varying degrees of bile duct proliferation in the presence or absence of phenobarbital tides, determined by 32 P-post-labelling, resulted in five out of Table I . Effects of α-hydroxytamoxifen treatment on the numbers and areas of GST-P foci Treatment GST-P foci Number (foci/cm -2 ) a Area (%) a 3 months 6 months 13 months 13 months when promoted with phenobarbital (6). In contrast, no animal had liver tumours at this time without phenobarbital promotion. DNA damage of 2800 adducts/10 8 nucleotides seen after 6 months continuous tamoxifen treatment, resulted in three hydroxytamoxifen is not sufficient to lead to the development of hepatocellular carcinomas even with phenobarbital promotion. While qualitatively, the pattern of adducts formed in the liver following dosing with tamoxifen or α-hydroxytamoxifen are the same, the relative proportions of the different adducts differ. Not all of the DNA damage detected may be directly associated with the subsequent development of liver tumours. This has been established, for example, with a number of N-nitrosodialkylamine alkylating agents where most of the ring nitrogen atoms and the exocyclic oxygen atoms of guanine residues in DNA are targets (33) , but all are not equivalent in terms of carcinogenic potential (34). Defining the relationship between the level of DNA damage and the length of time needed to allow promotion and progression of transformed cells will be of importance in understanding the mechanism of carcinogenicity.
Controls
